Allocating Resources for Cancer Care in Times of the Sars-CoV-2 Outbreak. Health Care Research

NCT05479292 | Completed

• 1 other identifier: CancerCOVID-HCR
• Study Type: observational
• Target: 6,500
• Locations: 1 country
• Sites: 1

Brief Summary

The focus on treatment of COVID19 patients during the Sars-CoV-2 outbreak has most likely implications for the extent and quality of diagnosis and treatment of non-COVID19 patients. Medical care of cancer patients is a particularly sensitive area. To draw holistic conclusions, it is necessary to analyze the provision of healthcare as broadly as possible with regard to the dimensions of access, processes and outcome during the Sars-CoV-2 pandemic. This will be implemented exemplarily for the early detection, diagnosis and treatment of colorectal cancer (CRC) and pancreatic cancer (PaCa) in Saxony. Patients with diagnosis, treatment or early detection measures for type 2 diabetes (T2D), coronary heart disease (CHD) and multiple sclerosis (MS) serve as comparison groups.

Conditions

Colorectal Cancer (CRC) and Pancreatic Cancer (PaCa)

Outcome Measures

Primary Outcomes (2)

• Number of confirmed diagnoses (new cases of CRC or PaCa)

  Comparison of 2019 to 2020

• Number of colonoscopies

  Comparison of 2019 to 2020

Secondary Outcomes (2)

• Number of hospitalizations

  Comparison of 2019 to 2020

• Number of surgeries/systemic therapies related to cancer after onset of disease

  Comparison of 2019 to 2020

Other Outcomes (1)

• Pathway of health care

  Comparison of 2019 to 2020

Interventions

Sars-CoV-2 outbreak OTHER

Sars-CoV-2 pandemic's impact on provision of healthcare for cancer patients

Eligibility Criteria

• Age: 4 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Residents of Saxony, Germany with continuous health insurance coverage provided by the AOK PLUS from 2015 - 2020 with a diagnosis of colorectal cancer, pancreatic cancer, type 2 diabetes, coronary heart disease or multiple sclerosis in 2019 or 2020 according to ICD-10

You may qualify if:

• Resident of Saxony, Germany with health insurance coverage provided by AOK PLUS
• Diagnosis of colorectal cancer, pancreatic cancer, type 2 diabetes, coronary heart disease or multiple sclerosis between in 2019 or 2020 according to ICD-10

You may not qualify if:

• Change of health insurance provider between 2015 and 2020
• Born after 2014
• Deceased between 2015-2018

Sponsors & Collaborators

• Technische Universität Dresden: lead
• German Federal Ministry of Education and Research: collaborator
• AOK PLUS: collaborator
• Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg: collaborator
• Ruhr-Universität Bochum: collaborator

Study Sites (1)

ZEGV

Dresden, Saxony, 01307, Germany

Location

MeSH Terms

Conditions

Colorectal Neoplasms; Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Jochen Schmitt, Dr. med.

  Technische Universität Dresden

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2022
• First Posted: July 29, 2022
• Study Start: January 1, 2019
• Primary Completion: December 31, 2020
• Study Completion: December 31, 2020
• Last Updated: July 29, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)